专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

US20060155118A1 Affinity purification system using troponin molecules as affinity ligands 审中-公开
标题翻译：亲和纯化系统使用肌钙蛋白分子作为亲和配体
公开(公告)号：US20060155118A1
公开(公告)日：2006-07-13
申请号：US11369285
申请日：2006-03-06
申请人： Randolph Moeckli , Christopher Chadwick
发明人： Randolph Moeckli , Christopher Chadwick
IPC分类号： C12P21/04
CPC分类号： C12N15/62 , C07K14/47 , C07K14/4716 , C07K2319/20
摘要： This invention pertains to the use of a novel set of tags for the immobilization and/or purification of proteins or other biological or organic molecules. The invention provides troponin C, troponin C binding peptide, and troponin I, or active fragments or analogues thereof as convenient tags and affinity ligands for immobilizing, attaching, or purifying proteins or other molecules. Methods for producing troponin-tagged molecules, such as recombinant fusion proteins, are described. Methods for preparing a troponin affinity matrix that is capable of specifically binding its cognate ligand in the presence of calcium, and methods for using such a matrix to purify troponin-tagged molecules are also described.
摘要翻译：本发明涉及用于蛋白质或其他生物或有机分子的固定和/或纯化的新型标签的使用。本发明提供肌钙蛋白C，肌钙蛋白C结合肽和肌钙蛋白I或其活性片段或类似物作为用于固定，附着或纯化蛋白质或其他分子的方便的标签和亲和配体。描述了产生肌钙蛋白标签分子的方法，如重组融合蛋白。还描述了在钙的存在下能够特异性结合其同源配体的肌钙蛋白亲和基质的制备方法，以及使用这种基质纯化肌钙蛋白标记的分子的方法。

2. 发明授权

US06917399B2 Optical bodies containing cholesteric liquid crystal material and methods of manufacture 失效
标题翻译：含有胆固醇液晶材料的光学体及其制造方法
公开(公告)号：US06917399B2
公开(公告)日：2005-07-12
申请号：US09791157
申请日：2001-02-22
申请人： Richard John Pokorny , Marc Dudley Radcliffe , Philip Edwin Watson , Christopher Chadwick Bowley , Ikuko Ebihara
发明人： Richard John Pokorny , Marc Dudley Radcliffe , Philip Edwin Watson , Christopher Chadwick Bowley , Ikuko Ebihara
IPC分类号： G02B5/30 , G02F1/1335 , C09K19/02 , G02B27/28
CPC分类号： G02B5/3016
摘要： An optical body includes a substrate and a cholesteric liquid crystal layer disposed on the substrate. The cholesteric liquid crystal layer has a non-uniform pitch along a thickness direction of the layer and comprises a crosslinked polymer material that substantially fixes the cholesteric liquid crystal layer. The crosslinking hinders diffusion of cholesteric liquid crystal material within the cholesteric liquid crystal layer. In other methods of making an optical body, a reservoir of chiral material is provided during the process over a first cholesteric liquid crystal layer to diffuse into the layer and provide a non-uniform pitch. Alternatively, two coating compositions can be disposed on a substrate where the material of the first coating composition is not substantially soluble in the second coating composition.
摘要翻译：光学体包括衬底和设置在衬底上的胆甾型液晶层。胆甾型液晶层沿着该层的厚度方向具有不均匀的间距，并且包括基本上固定胆甾醇型液晶层的交联聚合物材料。交联阻碍胆甾型液晶材料在胆甾型液晶层内的扩散。在制造光学体的其它方法中，在第一胆甾醇型液晶层的过程中提供手性材料的储存器以扩散到该层中并提供不均匀的间距。或者，两个涂料组合物可以设置在基材上，其中第一涂料组合物的材料基本上不溶于第二涂料组合物。

3. 发明申请

US20050113405A1 Methods of treating rheumatoid arthritis using NF-kB inhibitors 审中-公开
标题翻译：使用NF-kB抑制剂治疗类风湿关节炎的方法
公开(公告)号：US20050113405A1
公开(公告)日：2005-05-26
申请号：US10947900
申请日：2004-09-23
申请人： Douglas Harnish , Christopher Chadwick , James Keith
发明人： Douglas Harnish , Christopher Chadwick , James Keith
IPC分类号： A61K31/416 , A61K31/473
CPC分类号： A61K31/416 , A61K31/473
摘要： The present invention concerns a method of treating rheumatoid arthritis by diagnosing that a person is in need of treatment for rheumatoid arthritis and administering a therapeutically effective amount of a ligand which modulates NF-kB transcription factor by interaction with estrogen receptor ER-α, estrogen receptor ER-β, or both ER-α and ER-β estrogen receptors with a substantial absence of creatine kinase stimulation. In certain embodiments, the administration is with a substantial absence of uterotropic activity.
摘要翻译：本发明涉及一种通过诊断人类需要治疗类风湿性关节炎并且通过与雌激素受体ER-α，雌激素受体相互作用来施用治疗有效量的调节NF-kB转录因子的配体来治疗类风湿性关节炎的方法 ER-β或ER-α和ER-β雌激素受体，而肌酸激酶刺激基本上不存在。在某些实施方案中，施用基本上不存在子活性。

4. 发明授权

US07320020B2 Mail server probability spam filter 有权
标题翻译：邮件服务器概率垃圾邮件过滤器
公开(公告)号：US07320020B2
公开(公告)日：2008-01-15
申请号：US10418006
申请日：2003-04-17
申请人： Michael Christopher Chadwick , Adam Thomas Sink , Blake Schwendiman
发明人： Michael Christopher Chadwick , Adam Thomas Sink , Blake Schwendiman
IPC分类号： G06F15/16
CPC分类号： H04L51/12
摘要： Email senders may transmit emails over the internet to a mail server that handles emails for a plurality of users (clients). The mail server may use a spam filter to remove the spam and then transmit the filtered emails to the addressed clients. The spam filter may use a white list, black list, probability filter and keyword filter. The probability filter may use a user mail corpus and a user spam corpus for creating a user probability table that lists tokens and the probability that an email is a spam if the email contains the token. The probability filter may also use a general mail corpus and a general spam corpus for creating a general probability table that. Tokens of incoming emails may be searched for in the user probability table, and if not found, the general probability table to calculate the probability that the email is a spam.
摘要翻译：电子邮件发送者可以通过互联网将电子邮件发送到处理多个用户（客户端）的电子邮件的邮件服务器。邮件服务器可以使用垃圾邮件过滤器来删除垃圾邮件，然后将已过滤的电子邮件传送到寻址的客户端。垃圾邮件过滤器可以使用白名单，黑名单，概率过滤器和关键字过滤器。概率过滤器可以使用用户邮件语料库和用户垃圾邮件语料库来创建列出令牌的用户概率表以及如果电子邮件包含令牌，则电子邮件是垃圾邮件的概率。概率滤波器还可以使用通用邮件语料库和一般垃圾邮件语料库来创建一般概率表。可以在用户概率表中搜索传入电子邮件的令牌，如果没有找到，则计算电子邮件是垃圾邮件的概率的一般概率表。

5. 发明申请

US20060111421A1 Method of treating or preventing myocardial ischemia-reperfusion injury using NF-kB inhibitors 失效
标题翻译：使用NF-kB抑制剂治疗或预防心肌缺血再灌注损伤的方法
公开(公告)号：US20060111421A1
公开(公告)日：2006-05-25
申请号：US11206233
申请日：2005-08-17
申请人： Christopher Chadwick , Douglas Harnish
发明人： Christopher Chadwick , Douglas Harnish
IPC分类号： A61K31/416
CPC分类号： A61K31/416
摘要： The present invention concerns a method of treatment or prevention of myocardial ischemia-reperfusion injury by diagnosing that a person is in need of treatment or prevention of myocardial ischemia-reperfusion injury and administering a therapeutically effective amount of a ligand which modulates NF-kB transcription factor by interaction with estrogen receptor ER-α, estrogen receptor ER-β, or both ER-α and ER-β estrogen receptors with a substantial absence of creatine kinase stimulation. In certain preferred embodiments, the administration is substantially without uterotropic activity.
摘要翻译：本发明涉及通过诊断人需要治疗或预防心肌缺血再灌注损伤来治疗或预防心肌缺血再灌注损伤的方法，并且施用治疗有效量的调节NF-κB转录因子的配体通过与雌激素受体ER-α，雌激素受体ER-β或ER-α和ER-β雌激素受体的相互作用，基本上不存在肌酸激酶刺激。在某些优选的实施方案中，给药基本上不具有子宫活性。

6. 发明申请

US20050240511A1 Investment system 审中-公开
标题翻译：投资体系
公开(公告)号：US20050240511A1
公开(公告)日：2005-10-27
申请号：US10939476
申请日：2004-09-14
申请人： Christopher Chadwick , Raglan Andrew Harold Tribe
发明人： Christopher Chadwick , Raglan Andrew Harold Tribe
IPC分类号： G06Q10/00 , G06F17/60
CPC分类号： G06Q10/06 , G06Q40/04
摘要： An investment system for projects seeking funding, such as pre-trading enterprises, is disclosed. The system comprises a share allocation facility for allocating shares to a project on the basis of the funding that they require, and a stock exchange for trading shares in the project. During development of the project, the project is required to meet a number of development goals, and its progress through each of the development goals is audited. The results of the audit are published and may affect the share price in the project.
摘要翻译：披露了前期交易企业等资金项目投资制度。该系统包括根据所需资金分配股份给项目的股份分配机构，以及项目交易股票交易所。在项目开发过程中，项目需要达到一定的发展目标，每个发展目标的进度都得到审计。审计结果公布，可能影响项目的股价。

7. 发明申请

US20050043510A1 Affinity purification system using troponin molecules as affinity ligands 审中-公开
标题翻译：亲和纯化系统使用肌钙蛋白分子作为亲和配体
公开(公告)号：US20050043510A1
公开(公告)日：2005-02-24
申请号：US10820998
申请日：2004-04-07
申请人： Randolph Moeckli , Christopher Chadwick
发明人： Randolph Moeckli , Christopher Chadwick
IPC分类号： C07K14/47 , C12N15/62 , C12P21/04
CPC分类号： C12N15/62 , C07K14/47 , C07K14/4716 , C07K2319/20
摘要： This invention pertains to the use of a novel set of tags for the immobilization and/or purification of proteins or other biological or organic molecules. The invention provides troponin C, troponin C binding peptide, and troponin I, or active fragments or analogues thereof as convenient tags and affinity ligands for immobilizing, attaching, or purifying proteins or other molecules. Methods for producing troponin-tagged molecules, such as recombinant fusion proteins, are described. Methods for preparing a troponin affinity matrix that is capable of specifically binding its cognate ligand in the presence of calcium, and methods for using such a matrix to purify troponin-tagged molecules are also described.
摘要翻译：本发明涉及用于蛋白质或其他生物或有机分子的固定和/或纯化的新型标签的使用。本发明提供肌钙蛋白C，肌钙蛋白C结合肽和肌钙蛋白I或其活性片段或类似物作为用于固定，附着或纯化蛋白质或其他分子的方便的标签和亲和配体。描述了产生肌钙蛋白标签分子的方法，如重组融合蛋白。还描述了在钙的存在下能够特异性结合其同源配体的肌钙蛋白亲和基质的制备方法，以及使用这种基质纯化肌钙蛋白标记的分子的方法。

8. 发明申请

US20050119276A1 Methods of treating inflammatory bowel disease using NF-kB inhibitors 审中-公开
标题翻译：使用NF-kB抑制剂治疗炎症性肠病的方法
公开(公告)号：US20050119276A1
公开(公告)日：2005-06-02
申请号：US10948018
申请日：2004-09-23
申请人： Douglas Harnish , Christopher Chadwick , James Keith
发明人： Douglas Harnish , Christopher Chadwick , James Keith
IPC分类号： A61K31/416 , A61K31/473 , A61K31/496
CPC分类号： A61K31/496 , A61K31/416 , A61K31/473
摘要： The present invention concerns a method of treating inflammatory bowel disease by diagnosing that a person is in need of treatment for inflammatory bowel disease and administering a therapeutically effective amount of a ligand which modulates NF-kB transcription factor by interaction with estrogen receptor ER-α, estrogen receptor ER-β, or both ER-α and ER-β estrogen receptors with a substantial absence of creatine kinase stimulation. In certain preferred embodiments, the administration is substantially without uterotropic activity.
摘要翻译：本发明涉及一种通过诊断一个人需要治疗炎性肠病并且通过与雌激素受体ER-α相互作用来施用治疗有效量的调节NF-kB转录因子的配体来治疗炎性肠病的方法，雌激素受体ER-β或ER-α和ER-β雌激素受体两者，而肌酐激酶刺激基本上不存在。在某些优选的实施方案中，给药基本上不具有子宫活性。

9. 发明申请

US20080133682A1 MAIL SERVER PROBABILITY SPAM FILTER 有权
标题翻译：邮件服务器概率垃圾邮件过滤器
公开(公告)号：US20080133682A1
公开(公告)日：2008-06-05
申请号：US11873329
申请日：2007-10-16
申请人： Michael Christopher Chadwick , Adam Thomas Sink , Blake Schwendiman
发明人： Michael Christopher Chadwick , Adam Thomas Sink , Blake Schwendiman
IPC分类号： G06F15/16
CPC分类号： H04L51/12
摘要： Email senders may transmit emails over the internet to a mail server that handles emails for a plurality of users (clients). The mail server may use a spam filter to remove the spam and then transmit the filtered emails to the addressed clients. The spam filter may use a white list, black list, probability filter and keyword filter. The probability filter may use a user mail corpus and a user spam corpus for creating a user probability table that lists tokens and the probability that an email is a spam if the email contains the token. The probability filter may also use a general mail corpus and a general spam corpus for creating a general probability table that. Tokens of incoming emails may be searched for in the user probability table, and if not found, the general probability table to calculate the probability that the email is a spam.
摘要翻译：电子邮件发送者可以通过互联网将电子邮件发送到处理多个用户（客户端）的电子邮件的邮件服务器。邮件服务器可以使用垃圾邮件过滤器来删除垃圾邮件，然后将已过滤的电子邮件传送到寻址的客户端。垃圾邮件过滤器可以使用白名单，黑名单，概率过滤器和关键字过滤器。概率过滤器可以使用用户邮件语料库和用户垃圾邮件语料库来创建列出令牌的用户概率表以及如果电子邮件包含令牌，则电子邮件是垃圾邮件的概率。概率滤波器还可以使用通用邮件语料库和一般垃圾邮件语料库来创建一般概率表。可以在用户概率表中搜索传入电子邮件的令牌，如果没有找到，则计算电子邮件是垃圾邮件的概率的一般概率表。

10. 发明申请

US20050119324A1 Methods of treating atherosclerosis using NF-kB inhibitors 审中-公开
标题翻译：使用NF-kB抑制剂治疗动脉粥样硬化的方法
公开(公告)号：US20050119324A1
公开(公告)日：2005-06-02
申请号：US10947901
申请日：2004-09-23
申请人： Douglas Harnish , Christopher Chadwick
发明人： Douglas Harnish , Christopher Chadwick
IPC分类号： A61K31/416
CPC分类号： A61K31/416
摘要： The present invention concerns a method of treating atherosclerosis by diagnosing that a person is in need of treatment for atherosclerosis and administering a therapeutically effective amount of a ligand which modulates NF-kB transcription factor by interaction with estrogen receptor ER-α, estrogen receptor ER-β, or both ER-α and ER-β estrogen receptors with a substantial absence of creatine kinase stimulation. In certain preferred embodiments, the administration is substantially without uterotropic activity.
摘要翻译：本发明涉及一种通过诊断人需要动脉粥样硬化治疗来治疗动脉粥样硬化的方法，并且通过与雌激素受体ER-α，雌激素受体ER-α相互作用来施用治疗有效量的调节NF-κB转录因子的配体， β或ER-α和ER-β雌激素受体，而肌酸激酶刺激基本上不存在。在某些优选的实施方案中，给药基本上不具有子宫活性。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式